Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 307 participants.

Also called NCT04534114

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 307 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04534114
  • EudraCT 2019-003927-39
Other papers using this trial's data
  • A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis Kidney international, 2024-07 DOI, PubMed 38537676

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Belgium, Bulgaria, Canada, Czechia, Germany, Greece, Hungary, Japan, Latvia, Russia, South Korea, Spain, Taiwan, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04534114. Randomized; quadruple masking; primary purpose treatment. Start 2020-09-04 (actual); primary completion 2022-01-24 (actual). Results posted on 2023-07-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug
Acronym
RE-THINc ESRD
Condition
End Stage Renal Disease Requiring Hemodialysis
Intervention (Drug)
Fesomersen sodium (BAY2976217)
Intervention (Drug)
Placebo
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct04534114
Content hash
19f69abeda6115efd242fa242f683e846b70536740d26923cc9ee95550235ce8